Skip to main content
Clinical Trials/NL-OMON50757
NL-OMON50757
Completed
Phase 2

Tau Imaging in Tauopathies; Alzheimer's disease and Non-AD dementias - TITA

Vrije Universiteit Medisch Centrum0 sites200 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
dementia
Sponsor
Vrije Universiteit Medisch Centrum
Enrollment
200
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Eligibility Criteria

Inclusion Criteria

  • In order to be eligible to participate in this study, a subject must meet all
  • of the following criteria: , \- At least 35 years of age
  • \- Subjects must, in the opinion of the principal investigator/attending
  • neurologist, be able to tolerate the \[18F]AV1451 PET scan procedures and be
  • competent to make a well informed decision to participate in this study..,
  • Additional inclusion criteria per diagnostic group:, For probable AD dementia
  • \- A diagnosis of probable AD with at least intermediate likelihood according to
  • recently proposed NIA\-AA criteria27\. This will be determined using PET and/or
  • CSF evidence of A\* deposition., For \*MCI due to AD\* patients;
  • \- Patients must meet clinical criteria for MCI25, and;

Exclusion Criteria

  • No MRI available or possible
  • Abnormalities on MRI which may interfere with PET image assessment:
  • Is or may become pregnant in the first 24h after the PET scan
  • Relevant history of drug allergy or hypersensitivity
  • Has ever recieved a tau and/or amyloid\-beta targetting agent
  • Has been injected with a previously administered radiopharmaceutical within 6
  • terminal half\-lives OR the total yearly radiation exposure exceeds 10 mSv;
  • Has a history of moderate or severe traumatic brain injury (TBI).

Outcomes

Primary Outcomes

Not specified

Similar Trials